EPAS1 mRNA in plasma from colorectal cancer patients is associated with poor outcome in advanced stages

Mohammed,N.; Rodriguez,M.; Garcia,V.; Garcia,J. M.; Dominguez,G.; Peña,C.; Herrera,M.; Gomez,I.; Diaz,R.; Soldevilla,B.; Herrera,A.; Silva,J.; Bonilla,F.

doi:10.3892/ol.2011.294

EPAS1 mRNA in plasma from colorectal cancer patients is associated with poor outcome in advanced stages

Authors:
- N. Mohammed
- M. Rodriguez
- V. Garcia
- J. M. Garcia
- G. Dominguez
- C. Peña
- M. Herrera
- I. Gomez
- R. Diaz
- B. Soldevilla
- A. Herrera
- J. Silva
- F. Bonilla
View Affiliations

Affiliations: Department of Medical Oncology, University Hospital Puerta de Hierro Majadahonda, E-28222 Madrid, Spain
Published online on: April 28, 2011 https://doi.org/10.3892/ol.2011.294
Pages: 719-724

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The presence of free nucleic acids in plasma has been detected in cancer patients and is associated with poor prognosis. In the present study, the mRNA levels of three genes (EPAS1, KIAA0101 and UBE2D3) in plasma from colorectal cancer patients were analyzed. These genes were selected from a previous study of genomic profiles, discriminating between healthy controls and colorectal cancer patients. mRNA levels were analyzed by real-time PCR in the plasma of 154 patients with colorectal cancer. The association of plasma mRNA levels with clinicopathological parameters and patient survival were analyzed. High levels of EPAS1 in the plasma were associated with patients aged over 50 years, relapse of disease and patient mortality. When patients were divided into two groups, early (I and II) and advanced (III and IV) stages, an association was observed between high levels of EPAS1 mRNA and worse disease-free and overall survival in advanced stages. The expression of KIAA0101 and UBE2D3 was not associated with poor prognosis. Thus, our results suggest that EPAS1 mRNA levels may be an indicator of poor prognosis in colorectal cancer patients at advanced stages, obtained by a non-invasive method.

View Figures

View References

1	Schoen RE: The case for population-based screening for colorectal cancer. Nat Rev Cancer. 2:65–70. 2002. View Article : Google Scholar : PubMed/NCBI
2	Fleischhacker M and Schmidt B: Circulating nucleic acids (CNAs) and cancer – a survey. Biochim Biophys Acta. 1775:181–232. 2007.
3	Leon SA, Shapiro B, Sklaroff DM and Yaros MJ: Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 37:646–650. 1977.PubMed/NCBI
4	Shapiro B, Chakrabarty M, Cohn EM and Leon SA: Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer. 51:2116–2120. 1983. View Article : Google Scholar : PubMed/NCBI
5	Silva JM, Rodriguez R, Garcia JM, Muñoz C, Silva J, Dominguez G, Provencio M, España P and Bonilla F: Detection of epithelial tumour RNA in the plasma of colon cancer patients is associated with advanced stages and circulating tumour cells. Gut. 50:530–534. 2002. View Article : Google Scholar : PubMed/NCBI
6	Silva J, Silva JM, Garcia JM, Dominguez G and Bonilla F: RNA is more sensitive than DNA in identification of breast cancer patients bearing tumor nucleic acids in plasma. Gene Chromosome Cancer. 3:375–376. 2002. View Article : Google Scholar : PubMed/NCBI
7	Silva JM, Dominguez G, Silva J, Garcia JM, Sanchez A, Rodriguez O, Provencio M and Bonilla F: Detection of epithelial messenger RNA in the plasma of breast cancer patients is associated with poor prognosis tumor characteristics. Clin Cancer Res. 7:2821–2825. 2001.PubMed/NCBI
8	Dasi F, Lledo S, Garcia-Granero E, Ripoll R, Marugan M, Tormo M, Garcia-Conde J and Aliño SF: Real-time quantification in plasma of human telomerase reverse transcriptase (hTERT) mRNA: a simple blood test to monitor disease in cancer patients. Lab Invest. 81:767–769. 2001. View Article : Google Scholar : PubMed/NCBI
9	Wong SC, Lo SF, Cheung MT, Ng KO, Tse CW, Lai BS, Lee KC and Lo YM: Quantification of plasma catenin mRNA in colorectal cancer and adenoma patients. Clin Cancer Res. 10:1613–1617. 2004. View Article : Google Scholar : PubMed/NCBI
10	Garcia V, Garcia JM, Peña C, Silva J, Dominguez G, Lorenzo Y, Diaz R, Espinosa P, Garcia de Sola J, Cantos B and Bonilla F: Free circulating mRNA in plasma from breast cancer patients and clinical outcome. Cancer Lett. 263:312–320. 2008. View Article : Google Scholar : PubMed/NCBI
11	Garcia V, Garcia JM, Peña C, Silva J, Dominguez G, Hurtado A, Alonso I, Rodriguez R, Provencio M and Bonilla F: Thymidylate synthase mRNA expression in plasma from colon cancer patients. Clin Cancer Res. 12:2095–2100. 2006. View Article : Google Scholar : PubMed/NCBI
12	Collado M, Garcia V, Garcia JM, Alonso I, Lombardia L, Diaz-Uriarte R, Fernandez Luis Lopez, Zaballos A, Bonilla F and Serrano M: Genomic profiling of circulating plasma RNA for the analysis of cancer. Clin Chem. 53:1860–1863. 2007. View Article : Google Scholar : PubMed/NCBI
13	Pilarsky C, Wenzig M, Specht T, Saeger HD and Grutzmann R: Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. Neoplasia. 6:744–750. 2004. View Article : Google Scholar : PubMed/NCBI
14	Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM: Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci USA. 101:9309–9314. 2004. View Article : Google Scholar : PubMed/NCBI
15	Yoshimura H, Dhar DK, Kohno H, Kubota H, Fujii T, Ueda S, Kinugasa S, Tachibana M and Nagasue N: Prognostic impact of hypoxia-inducible factors 1alpha and 2alpha in colorectal cancer patients: correlation with tumor angiogenesis and cyclooxygenase-2 expression. Clin Cancer Res. 10:8554–8560. 2004. View Article : Google Scholar : PubMed/NCBI
16	Saville MK, Sparks A, Xirodimas DP, Wardrop J, Stevenson LF, Bourdon JC, Woods YL and Lane DP: Regulation of p53 by the ubiquitin-conjugating enzymes UbcH5B/C in vivo. J Biol Chem. 279:42169–42181. 2004. View Article : Google Scholar : PubMed/NCBI
17	Gonen H, Bercovich B, Orian A, Carrano A, Takizawa C, Yamanaka K, Pagano M, Iwai K and Ciechanover A: Identification of the ubiquitin carrier proteins, E2s, involved in signal-induced conjugation and subsequent degradation of IkappaBalpha. J Biol Chem. 74:14823–14830. 1999. View Article : Google Scholar : PubMed/NCBI
18	Garcia JM, Garcia V, Peña C, Dominguez G, Silva J, Diaz R, Espinosa P, Citores MJ, Collado M and Bonilla F: Extracellular plasma RNA from colon cancer patients is confined in a vesicle-like structure and is mRNA-enriched. RNA. 14:1424–1432. 2008. View Article : Google Scholar : PubMed/NCBI
19	Al-Nedawi K, Meehan B, Micallef J, Lhotak V, May L, Guha A and Rak J: Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumor cells. Nat Cell Biol. 10:619–624. 2008. View Article : Google Scholar : PubMed/NCBI
20	Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ and Lötvall JO: Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 9:654–659. 2007. View Article : Google Scholar : PubMed/NCBI
21	Skog J, Würdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, Curry WT Jr, Carter BS, Krichevsky AM and Breakefield XO: Gliobastoma microvesicles transport RNA and proteins that promote tumor growth and provide diagnostic biomarkers. Nat Cell Biol. 10:1470–1476. 2008. View Article : Google Scholar : PubMed/NCBI
22	Hasselmann DO, Rappl G, Rossler M, Ugurel S, Tilgen W and Reinhold U: Detection of tumor-associated circulating mRNA in serum, plasma and blood cells from patients with disseminated malignant melanoma. Oncol Res. 8:115–118. 2001.PubMed/NCBI
23	Kopreski MS, Benko FA and Gocke CD: Circulating RNA as a tumor messenger in the serum of patient of malignant melanoma. Clin Cancer Res. 5:1961–1965. 1999.
24	Duffy MJ, van Dalen A, Haglund C, Hansson L and Kalapdor R: Clinical utility of biochemical markers in colorectal cancer: European Group on tumor markers (EGTM). Eur J Cancer. 39:718–727. 2003. View Article : Google Scholar : PubMed/NCBI
25	Bertout JA, Patel SA and Simon MC: The impact of O₂ availability on human cancer. Nat Rev Cancer. 8:967–975. 2008.
26	Wouters BG and Koritzinsky M: Hypoxia signaling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer. 8:851–864. 2008. View Article : Google Scholar : PubMed/NCBI
27	Erler JT, Bennewith KL, Nicolau M, Dornhofer N, Kong C, Le QT, Chi JT, Jeffrey SS and Giaccia AJ: Lysyl oxidase is essential for hypoxia-induced metastasis. Nature. 440:1222–1226. 2006. View Article : Google Scholar : PubMed/NCBI
28	Flamme I, Krieg M and Plate KH: Up-regulation of vascular endothelial growth factor in stromal cells of hemangioblastomas is correlated with up-regulation of the transcription factor HRF/HIF-2alpha. Am J Pathol. 153:25–29. 1998. View Article : Google Scholar : PubMed/NCBI
29	Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ and Harris AL: The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol. 157:411–421. 2000. View Article : Google Scholar : PubMed/NCBI
30	Baba Y, Nosho K, Shima K, Irahara N, Chan AT, Meyerhardt JA, Chung DC, Giovannucci EL, Fuchs CS and Ogino S: HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers. Am J Pathol. 176:2292–2301. 2010. View Article : Google Scholar : PubMed/NCBI
31	Rasheed S, Harris AL, Tekkis PP, Turley H, Silver A, McDonald PJ, Talbot IC, Glynne-Jones R, Northover JM and Guenther T: Hypoxia-inducible factor-1α and -2α are expressed in most rectal cancers but only hypoxia-inducible factor-1 α is associated with prognosis. Br J Cancer. 100:1666–1673. 2009.
32	Yoshimura H, Dhar DK, Kohno H, Kubota H, Fujii T, Ueda S, Kinugasa S, Tachibana M and Nagasue N: Prognostic impact of hypoxia-inducible factors 1α and 2α in colorectal cancer patients: correlation with tumor angiogenesis and cyclooxygenase-2 expression. Clin Cancer Res. 10:8554–8560. 2004.